Dissection of triple-negative breast cancer microenvironment and identification of potential therapeutic drugs using

Weilun Cheng1, Wanqi Mi2, Shiyuan Wang3

  • 1Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.

PubMed

Insights

Triple-negative breast cancer (TNBC) shows high heterogeneity and specific cell proliferation patterns. Targeting malignant epithelial cells and their microenvironment, like with pelitinib, offers new therapeutic strategies for aggressive breast cancer.

Area of Science:

  • Oncology
  • Genomics
  • Cancer Biology

Background:

  • Breast cancer is a leading cause of female mortality worldwide.
  • Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis and limited therapeutic options.
  • Tumor heterogeneity and microenvironment complexity present significant challenges in TNBC treatment.

Purpose of the Study:

  • To investigate the heterogeneity and cellular landscape of breast cancer, focusing on TNBC.
  • To identify specific cell types and molecular pathways driving TNBC progression.
  • To explore potential therapeutic targets and drugs for TNBC treatment.

Main Methods:

  • Single-cell RNA sequencing of tumor and healthy breast tissue.
  • Pseudotime trajectory analysis to associate oncogenes with tumor grade and prognosis.
  • Comprehensive characterization of the TNBC microenvironment.
  • In vivo validation using an orthotopic 4T1 tumor-bearing mouse model.

Main Results:

  • High heterogeneity was observed in breast cancer, with TNBC showing specific proliferation and differentiation patterns.
  • A highly malignant epithelial subcluster (E8) was identified, strongly associated with TNBC cell proliferation.
  • Epithelial-mesenchymal transition (EMT)-associated fibroblasts and M2 macrophages influence E8, promoting tumor growth.
  • Pelitinib demonstrated anti-cancer effects in a TNBC mouse model.

Conclusions:

  • TNBC exhibits unique single-cell characteristics and crucial cell types driving proliferation.
  • Specific genes within malignant epithelial cells, fibroblasts, and macrophages are potential therapeutic targets.
  • Pelitinib shows promise as an effective therapeutic drug for TNBC.

Related Concept Videos